Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAvMed Aliqopa IV Prior Auth Policy Update | OpenPa…
    Ask Trek AI about this page
    CurrentAvMedPolicy Pub. 100-2

    Aliqopa (copanlisib) IV prior authorization for relapsed follicular lymphoma

    Customize your policy alerts

    Sign up for AvMed Policy Pub. 100-2 alerts

    Get alerted when Policy Pub. 100-2 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Covers medical prior authorization requirements for Aliqopa (copanlisib) administered IV for AvMed members; describes required provider, member, and clinical documentation and criteria for approval. Affects prescribers, administering sites, and members seeking coverage for this drug.

    Policy Summary
    PayerAvMed
    PolicyAliqopa (copanlisib) IV prior authorization for relapsed follicular lymphoma
    Policy CodePolicy Pub. 100-2
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionObtain prior authorization via fax with a signed prescriber request form and supporting clinical documentation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    >=18minimum age for covered members
    >=2required prior therapies
    60 mg

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    single dose
    Days 1,8,15dosing schedule
    fax 1-877-535-1391submission fax

    Coverage Criteria for Aliqopa (copanlisib) IV

    inv-01: Initial therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met

    Age: Member is age 18 years or older>=18
    Prescriber specialty: Prescribing physician is an oncologist or hematologist
    Diagnosis/prior therapies: Member has a diagnosis of relapsed follicular lymphoma, defined as having received at least two prior systemic therapies>=2 prior systemic therapies

    Documentation of prior therapies will be verified via pharmacy claims or chart notes

    Dose and schedule: Dosage approved for 60 mg administered IV on Days 1, 8, and 15 of a 28 day cycle60 mg; Days 1,8,15 q28 days

    The use of drug samples to initiate therapy does not satisfy step edit or preauthorization requirements. Requests for coverage must document prior therapies; previous treatments will be verified through pharmacy paid claims or submitted chart notes.

    Initial Therapy — Specific Approval Conditions

    inv-11: Initial therapy — 4 top-level nodes

    Age: Member is age 18 years or older>=18
    Prescriber: Prescribing physician is an oncologist or hematologist
    Prior therapies: Member has relapsed follicular lymphoma and has received at least two prior systemic therapies>=2 prior systemic therapies

    Previous therapies will be verified through pharmacy claims or chart notes

    Dose:

    Billing and Code Information

    Covered HCPCS CodesHCPCSCovered
    J9999Aliqopa (copanlisib) IV - unspecified HCPCS
    C9399Aliqopa (copanlisib) IV - unclassified chemotherapy
    Single dose, copanlisib — 60 mg
    Single dose per administration60 mg
    Approved dosing schedule60 mg IV on Days 1, 8, and 15 of a 28-day cycle
    Route of administrationIntravenous infusion

    Provider Requirements and Submission Instructions

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for this medication. Submit requests by fax to 1-877-535-1391 using the signed prescriber request form (preprinted stamps are not valid). Include the HCPCS/administration codes J9999 and/or C9399 on the request as applicable. Allowable review types: standard review unless the practitioner requests an urgent review per AvMed definition.

    • Signed prescriber signature required (physician must sign and clearly print name)
    • Preprinted signature stamps are not valid
    • For urgent review, contact AvMed Pre-Authorization Department per urgent criteria
    Documentation Required

    Samples and Prior Therapy Verification

    Samples do not meet prior authorization or step-edit criteria and cannot be used to initiate therapy. Prior therapies listed on the request will be verified by the plan via pharmacy paid-claim history or submitted medical chart notes; provide documentation for prior systemic therapies when applicable.

    Administration Site Requirements

    Note

    Site of care — specify administering location and NPI/DEA (or specialty pharmacy)

    Indicate the location/site of drug administration and provide the NPI or DEA number of the administering location, or select the specialty pharmacy option (Proprium Rx) if applicable.

    • Provide administering location/site and NPI or DEA # of that location.
    • Option to designate Specialty Pharmacy - Proprium Rx.

    Clinical Background

    Follicular lymphoma is an indolent B‑cell non‑Hodgkin lymphoma that commonly relapses after systemic therapy. For relapsed disease, targeted agents such as PI3K inhibitors may be used; this policy addresses coverage for Aliqopa (copanlisib) IV for members with relapsed follicular lymphoma who have received at least two prior systemic therapies.

    Approval requires documentation that the patient is an adult (age >= 18 years), that the prescriber is an oncologist or hematologist, and that dosing follows the approved regimen (60 mg IV on Days 1, 8, and 15 of a 28‑day cycle). Providers must supply supporting clinical documentation and prior therapy records as noted; samples cannot be used to meet prior‑therapy requirements.

    Definitions and Key Terms

    Relapsed follicular lymphoma — defined as >= 2 prior systemic therapies
    DefinitionRelapsed follicular lymphoma defined as having received at least two prior systemic therapies
    Minimum prior therapies required>= 2 prior systemic therapies
    Documentation requirementDocumentation of prior therapies must be provided (lab results, diagnostics, and/or chart notes) or request may be denied

    Step Therapy Requirements

    RequirementDetails
    Previous therapies must be documentedPrevious therapies will be verified through pharmacy paid claims or submitted chart notes
    Use of samples to initiate therapy does not satisfy step edit/preauthorization requirementsSamples alone do not meet prior authorization criteria; documentation of completed prior therapies is required
    Policy Summary
    PayerAvMed
    PolicyAliqopa (copanlisib) IV prior authorization for relapsed follicular lymphoma
    Policy CodePolicy Pub. 100-2
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionObtain prior authorization via fax with a signed prescriber request form and supporting clinical documentation.
    SourceLink
    On This Page
    Coverage Criteria for Aliqopa (copanlisib) IVInitial Therapy — Specific Approval ConditionsBilling and Code InformationProvider Requirements and Submission InstructionsAdministration Site RequirementsClinical BackgroundDefinitions and Key TermsStep Therapy Requirements
    60 mg IV on Days 1, 8, and 15 of 28-day cycle
    60 mg; Days 1,8,15 q28 days
    • Do not rely on samples to satisfy prior therapy requirements
    • Attach chart notes or ensure accurate pharmacy history to document prior systemic therapies
    Documentation Required

    Required Submission Information

    Provide complete prescriber, member, dosing, diagnosis, and prior therapy information. Incomplete requests may be delayed or denied — include weight and date obtained when weight-based dosing applies.

    • Prescriber name, NPI, phone and fax numbers
    • Member name and identifiers (as applicable)
    • Drug name/form/strength and dosing schedule (e.g., 60 mg IV on Days 1, 8, 15 of 28-day cycle)
    • Length of therapy and diagnosis with ICD-10 code
    • Weight and date weight obtained (if applicable)
    • Documentation of at least two prior systemic therapies for relapsed follicular lymphoma
    • Prescriber specialty (oncologist or hematologist) must be indicated
    Denial Risk

    Incomplete or Insufficient Documentation

    Authorization may be delayed or denied if the PA form or supporting documentation is missing, incomplete, illegible, or if clinical criteria are not fully met. Ensure all chart notes, lab results, and diagnostics that support requested criteria are included.

    • Illegible or missing information (including phone/fax) can delay review
    • Provide all supporting clinical documentation for each criterion checked on the form